| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 22.2 | 20.6 |
| Gross profit | 12.3 | 12.0 |
| Profit before tax | -2.7 | -1.1 |
| Net income | -2.6 | -1.2 |
| EPS (diluted, $ a share) | $-0.58 | $-0.28 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +7.8% |
|---|---|
| Gross margin | 55.4% |
| Operating margin | -5.2% |
10-Q filed with the SEC, NASDAQ: HBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Harvard Bioscience Inc: key numbers
- Share price
- $8.91Close, Nov 16
- Market cap
- $40.7M
- Shares outstanding
- 4.57MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Harvard Bioscience Inc
All →Harvard Bioscience Investor Presentation
Harvard Bioscience filed its updated corporate slide presentation for November 2026 to provide the investment community with updates and summaries of its business operations. The presentation includes forward-looking information regarding expected financial performance, including adjusted EBITDA margins and the introduction of new products aimed at accelerating drug development.
Harvard Bioscience Financial Results
Harvard Bioscience reported Q3 2026 revenue of $22.2 million, an 8% increase year-over-year, driven by strong demand from CROs and customers in China. The company reported a net loss of $2.6 million for the quarter and reaffirmed its full-year 2026 revenue growth guidance of 3% to 5%.
- Term
- Q3 2026
“We delivered our second consecutive quarter of strong year over year growth with an 8% topline increase in the third quarter. We saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and fluidics products.”
John Duke, President and Chief Executive Officer